Psychiatric comorbidities predict seizure recurrence in newly treated adults with epilepsy

At least 30 % to 40 % of patients newly treated for epilepsy experience further seizures despite initiation of appropriate antiseizure medication (ASM) treatment. This study aimed to identify clinically useful predictors of seizure recurrence in newly treated adults with epilepsy which would have major clinical benefits.

This work is a prospective cohort study conducted in Northeast China between June 2017 and May 2022. At enrolment, we collected information about demographics, clinical characteristics, and psychiatric comorbidities in newly treated adults with epilepsy. All patients were followed for 12 months for further seizures. Predictors of seizure recurrence were identified using logistic regression analyses.

A total of 836 newly treated adults with epilepsy were included in the final analysis. During follow-up, 362 (43.3 %) patients experienced at least one seizure recurrence, and 474 (56.7 %) entered seizure remission. Multivariable analysis showed that the odds of patients with depression having seizure recurrence were 1.74 times greater than those of patients without depression (Adjusted OR 1.74, 95 % CI 1.21-2.51). Similarly, the odds of patients with anxiety having seizure recurrence were 1.69 times greater than those of patients without anxiety (Adjusted OR 1.69, 95 % CI 1.21-2.37). Other Predictors of seizure recurrence included >5 seizures prior to treatment, brain MRI lesion, EEG epileptiform discharges.

We found that psychiatric comorbidities at baseline increase the risk of seizure recurrence in newly treated adults with epilepsy. Future studies are required to clarify the mechanisms underlying the links among psychiatric comorbidities and epilepsy. Furthermore, our findings might inform prospective studies investigating whether psychiatric treatment reduces the risk of seizure recurrence in these patients.